))
The Weight-Loss Shots Semaglutide and Tirzepatide: Controversy and Understanding their Use
Manage episode 364774421 series 2929270
Content provided by Dr. Jeffrey DeSarbo and Lukas DeSarbo, LMSW, Dr. Jeffrey DeSarbo, Lukas DeSarbo, and LMSW. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Jeffrey DeSarbo and Lukas DeSarbo, LMSW, Dr. Jeffrey DeSarbo, Lukas DeSarbo, and LMSW or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
This presentation is on the medications semaglutide and tirzepatide , prescribed under brand names such as Ozempic, Wegovy and Monjaro, and others, some of which are in development. These drugs are GLP-1 agonist medications most commonly used for the treatment of type 2 diabetes, but more recently it’s been in the spotlight as a medication for weight loss, causing controversy, misunderstanding, questions and significant shortages of the medication.
Dr. DeSarbo will briefly look at these medications from all perspectives including their use in diabetes, as a weight loss drug for the medical definition of obesity, and their potential impact and fallout with the eating disorder population.
3 episodes
Share
